Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The optimal level of counseling and frequency of attendance for medication distribution has not been established for the primary care, office-based buprenorphine-naloxone treatment of opioid dependence. METHODS: We conducted a 24-week randomized, controlled clinical trial with 166 patients assigned to one of three treatments: standard medical management and either once-weekly or thrice-weekly medication dispensing or enhanced medical management and thrice-weekly medication dispensing. Standard medical management was brief, manual-guided, medically focused counseling; enhanced management was similar, but each session was extended. The primary outcomes were the self-reported frequency of illicit opioid use, the percentage of opioid-negative urine specimens, and the maximum number of consecutive weeks of abstinence from illicit opioids. RESULTS: The three treatments had similar efficacies with respect to the mean percentage of opioid-negative urine specimens (standard medical management and once-weekly medication dispensing, 44 percent; standard medical management and thrice-weekly medication dispensing, 40 percent; and enhanced medical management and thrice-weekly medication dispensing, 40 percent; P=0.82) and the maximum number of consecutive weeks during which patients were abstinent from illicit opioids. All three treatments were associated with significant reductions from baseline in the frequency of illicit opioid use, but there were no significant differences among the treatments. The proportion of patients remaining in the study at 24 weeks did not differ significantly among the patients receiving standard medical management and once-weekly medication dispensing (48 percent) or thrice-weekly medication dispensing (43 percent) or enhanced medical management and thrice-weekly medication dispensing (39 percent) (P=0.64). Adherence to buprenorphine-naloxone treatment varied; increased adherence was associated with improved treatment outcomes. CONCLUSIONS: Among patients receiving buprenorphine-naloxone in primary care for opioid dependence, the efficacy of brief weekly counseling and once-weekly medication dispensing did not differ significantly from that of extended weekly counseling and thrice-weekly dispensing. Strategies to improve buprenorphine-naloxone adherence are needed. (ClinicalTrials.gov number, NCT00023283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whereas treatment outcomes did not vary significantly by treatment condition,5 patient satisfaction did (F[2, 139] = 3.16, P = .03).”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [5]
In the citing paper
“This paucity of research is particularly noteworthy given the increasing availability and demonstrated efficacy of office-based buprenorphine/naloxone treatment.5–7”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [5]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Effects of Psychosocial Services in Substance Abuse Treatment
McLellan, A. T. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500150065028 · Cited by 869
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577
Crits-Christoph, P. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.493 · Cited by 496
Ensuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461
Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Carroll, K. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00049-6 · Cited by 386
A Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence
Ling, W. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050035005 · Cited by 366
Psychotherapy and Pharmacotherapy for Ambulatory Cocaine Abusers
Carroll, K. M. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030013002 · Cited by 348
Buprenorphine vs Methadone Maintenance Treatment for Concurrent Opioid Dependence and Cocaine Abuse
Schottenfeld, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200041006 · Cited by 303
Self-citationBuprenorphine versus Methadone Maintenance for Opioid Dependence
KOSTEN, T. R., SCHOTTENFELD, R., ZIEDONIS, D., & FALCIONI, J. (1993) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199306000-00004 · Cited by 267
Self-citationThe effects of psychosocial services in substance abuse treatment
McLellan, A. T. (1993) · JAMA · doi:10.1001/jama.269.15.1953 · Cited by 248
Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005031.pub4 · Cited by 221
The Language of Medication-Taking
Steiner, J. F., & Earnest, M. A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-11-200006060-00026 · Cited by 189
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence
Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01186-2 · Cited by 183
Methadone Maintenance in Primary Care: A Randomized Controlled Trial
Fiellin, D. A., O'Connor, P. G., Chawarski, M., Pakes, J. P., Pantalon, M. V., & Schottenfeld, R. S. (2001) · JAMA · doi:10.1001/jama.286.14.1724 · Cited by 182
Self-citationO’Connor, P., Oliveto, A., Shi, J., Triffleman, E., Carroll, K., Kosten, T., Rounsaville, B., Pakes, J., & Schottenfeld, R. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00194-6 · Cited by 174
Self-citationHeroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use.
Hartel, D. M., Schoenbaum, E. E., Selwyn, P. A., Kline, J., Davenny, K., Klein, R. S., & Friedland, G. H. (1995) · American Journal of Public Health · doi:10.2105/ajph.85.1.83 · Cited by 169
George, T. P., Chawarski, M. C., Pakes, J., Carroll, K. M., Kosten, T. R., & Schottenfeld, R. S. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00310-8 · Cited by 159
Self-citationSullivan, L. E., Chawarski, M., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.12.008 · Cited by 110
Self-citationTreatment of heroin dependence with buprenorphine in primary care
Fiellin, D. A., Pantalon, M. V., Pakes, J. P., O'Connor, P. G., Chawarski, M., & Schottenfeld, R. S. (2002) · The American Journal of Drug and Alcohol Abuse · doi:10.1081/ada-120002972 · Cited by 98
Self-citationNew Federal Initiatives To Enhance the Medical Treatment of Opioid Dependence
Fiellin, D. A., & O'Connor, P. G. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-8-200210150-00014 · Cited by 96
Self-citationAlternate-day dosing during buprenorphine treatment of opioid dependence
Amass, L., Bickel, W. K., Higgins, S. T., & Badger, G. J. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00848-5 · Cited by 90
The French Experience – the Pharmacist, General Practitioner and Patient Perspective
Bouchez, J., & Vignau, J. (1998) · European Addiction Research · doi:10.1159/000052037 · Cited by 62
A Pilot Study of Primary-Care—Based Buprenorphine Maintenance for Heroin Dependence
O'Connor, P. G., Oliveto, A. H., Shi, J. M., Triffleman, E., Carroll, K. M., Kosten, T. R., & Rounsaville, B. J. (1996) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952999609001678 · Cited by 50
Self-citationFiellin, D. A., O’Connor, P. G., Chawarski, M. C., & Schottenfeld, R. S. (2004) · American Journal on Addictions · doi:10.1080/10550490490440843 · Cited by 16
Self-citationCounseling Requirements for Buprenorphine Maintenance in Primary Care
Pantalon, M. V., Fiellin, D. A., O’Connor, P. G., Chawarski, M. C., Pakes, J., & Schottenfeld, R. S. (2004) · Addictive Disorders & Their Treatment · doi:10.1097/00132576-200406000-00003 · Cited by 7
Self-citation
Research works printed but not linked: 1
- Amato L, 2004, Cochrane Database Syst Rev, 4, CD005031
Cited by
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 910
Self-citationStrang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 490
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461
“96 In these individuals, transitioning from buprenorphine to methadone may allow for improved treatment outcome.”
Background
Metadata
- Authors
- Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S.
- Affiliations
- Yale University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-07-27
- Volume
- 355
- Issue
- 4
- Pages
- 365-374
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1964032526
- Cited by
- 351
- References
- 30
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 17 · 2023: 14 · 2022: 13 · 2021: 28 · 2020: 18 · 2019: 24 · 2018: 22 · 2017: 19 · 2016: 11 · 2015: 19 · 2014: 18 · 2013: 18 · 2012: 15
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (K24DA000445, K23 DA15144, R01DA009803, K12 DA00167, K23DA015144, K12DA000167)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, buprenorphine/naloxone, medication-assisted treatment, counseling, primary care, medication adherence, opioid abstinence, urine drug testing, treatment retention
- MeSH terms
- Adult, Buprenorphine, Combined Modality Therapy, Counseling, Female, Humans, Male, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.